中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
2期
247-249
,共3页
刘敏%代利霞%张晓春%贺晓东
劉敏%代利霞%張曉春%賀曉東
류민%대리하%장효춘%하효동
羟苯磺酸钙%缬沙坦%蛋白尿%免疫球蛋白A肾病
羥苯磺痠鈣%纈沙坦%蛋白尿%免疫毬蛋白A腎病
간분광산개%힐사탄%단백뇨%면역구단백A신병
Calcium dobesilate%Valsartan%Proteinuria%IgA nephropathy
目的：：观察羟苯磺酸钙联合缬沙坦治疗免疫球蛋白A( IgA)肾病的疗效。方法：58例IgA肾病患者随机分为观察组和对照组,对照组给予缬沙坦160 mg·d-1,观察组给予羟苯磺酸钙500 mg,tid,联合缬沙坦160 mg·d-1,6个月后观察血压、血纤维蛋白原( FIB)、尿素氮( BUN)、血清肌酐( Scr)、血尿酸( UA)、24 h尿蛋白定量( Upro)等指标的变化情况。结果：治疗后两组UA、Upro较治疗前均有所下降,有统计学意义(P<0.05或0.01)。观察组Upro由(1.48±0.84) g/24 h降为(0.41±0.22) g/24 h,与对照组相比有统计学意义(P<0.05)。治疗后观察组BUN、Scr、FIB显著下降(P<0.05),但对照组相比差异无统计学意义(P>0.05)。结论：羟苯磺酸钙联合缬沙坦能有效降低IgA肾病患者尿蛋白量,改善其肾功能。
目的：：觀察羥苯磺痠鈣聯閤纈沙坦治療免疫毬蛋白A( IgA)腎病的療效。方法：58例IgA腎病患者隨機分為觀察組和對照組,對照組給予纈沙坦160 mg·d-1,觀察組給予羥苯磺痠鈣500 mg,tid,聯閤纈沙坦160 mg·d-1,6箇月後觀察血壓、血纖維蛋白原( FIB)、尿素氮( BUN)、血清肌酐( Scr)、血尿痠( UA)、24 h尿蛋白定量( Upro)等指標的變化情況。結果：治療後兩組UA、Upro較治療前均有所下降,有統計學意義(P<0.05或0.01)。觀察組Upro由(1.48±0.84) g/24 h降為(0.41±0.22) g/24 h,與對照組相比有統計學意義(P<0.05)。治療後觀察組BUN、Scr、FIB顯著下降(P<0.05),但對照組相比差異無統計學意義(P>0.05)。結論：羥苯磺痠鈣聯閤纈沙坦能有效降低IgA腎病患者尿蛋白量,改善其腎功能。
목적：：관찰간분광산개연합힐사탄치료면역구단백A( IgA)신병적료효。방법：58례IgA신병환자수궤분위관찰조화대조조,대조조급여힐사탄160 mg·d-1,관찰조급여간분광산개500 mg,tid,연합힐사탄160 mg·d-1,6개월후관찰혈압、혈섬유단백원( FIB)、뇨소담( BUN)、혈청기항( Scr)、혈뇨산( UA)、24 h뇨단백정량( Upro)등지표적변화정황。결과：치료후량조UA、Upro교치료전균유소하강,유통계학의의(P<0.05혹0.01)。관찰조Upro유(1.48±0.84) g/24 h강위(0.41±0.22) g/24 h,여대조조상비유통계학의의(P<0.05)。치료후관찰조BUN、Scr、FIB현저하강(P<0.05),단대조조상비차이무통계학의의(P>0.05)。결론：간분광산개연합힐사탄능유효강저IgA신병환자뇨단백량,개선기신공능。
Objective:To observe the clinical efficacy of calcium dobesilate combined with valsartan in the treatment of IgA ne-phropathy. Methods:Totally 58 cases of IgA nephropathy were randomly divided into the treatment group and the control group. The control group enrolled 29 cases given valsartan 160 mg · d-1 . The treatment group included 29 cases treated with calcium dobesilate 500 mg·time-1 ,tid,and valsartan 160 mg·d-1 . After 6 months, the following indicators were observed, such as blood pressure,fi-brinogen,urea nitrogen,serum creatinine,blood uric acid,and 24-hour urinary ( Upro) . Results: After 6 months, UA and Upro of the two groups were significantly declined than those before the treatment(the control group P<0. 05,the treatment group P<0. 01). Upro of the treatment group was declined from (1. 48 ± 0. 84) g/24h to (0. 41 ± 0. 22) g/24h,and there was statistical significance com-pared with the control group (P<0.05). BUN, Scr and FIB were decreased significantly(P <0.05),while no significant change showed in those in the control group after the treatment. Conclusion:Calcium dobesilate combined valsartan can effectively reduce Up-ro and improve renal function in IgA nephropathy.
